Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02523924 · ClinicalTrials.gov registry record · NA

Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy

A NA study of Adenocarcinoma of the Prostate, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT02523924 is a NA study of Adenocarcinoma of the Prostate that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 50 participants, below the 107-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02523924, a NA study of Adenocarcinoma of the Prostate, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.

Interventions

  • DRUG 18F-DCFPyL

Study Locations (1)

Maryland

  • SKCCC - Baltimore

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2015-06-02
Est. Completion 2019-03-04
Phase NA

What the Registry Record Tells You About NCT02523924

The ClinicalTrials.gov registry entry for NCT02523924 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (53% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 1 intervention - of which 18F-DCFPyL is the first listed.

NCT02523924 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT02523924 about?

NCT02523924 is a clinical study titled "Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy". This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.

What is the current status of trial NCT02523924?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2015-06-02. Estimated completion is 2019-03-04.

What conditions does trial NCT02523924 study?

This clinical trial studies the following conditions: Adenocarcinoma of the Prostate.

What interventions are being tested in trial NCT02523924?

The interventions under investigation include: 18F-DCFPyL (DRUG).

Who is sponsoring clinical trial NCT02523924?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02523924 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adenocarcinoma of the Prostate

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.